Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

 View HTML
0001047469-16-017106.pdf
0001047469-16-017106.rtf
0001047469-16-017106.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-010475.pdf
0001558370-16-010475.rtf
0001558370-16-010475.xls
SC 13G

A statement of beneficial ownership of common stock by certain persons

 View HTML
0001193805-16-004377.pdf
0001193805-16-004377.rtf
0001193805-16-004377.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000899243-16-036208.pdf
0000899243-16-036208.rtf
0000899243-16-036208.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-17-000061.pdf
0001558370-17-000061.rtf
0001558370-17-000061.xls
CT ORDER

CT ORDER

 View HTML
9999999997-17-000052.pdf
SC 13G

A statement of beneficial ownership of common stock by certain persons

 View HTML
0000215457-17-002178.pdf
0000215457-17-002178.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0000899243-17-003295.pdf
0000899243-17-003295.rtf
0000899243-17-003295.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000899243-17-003297.pdf
0000899243-17-003297.rtf
0000899243-17-003297.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0001193125-17-040526.pdf
0001193125-17-040526.rtf
0001193125-17-040526.xls